Aardvark Therapeutics (AARD) Accumulated Expenses (2024 - 2026)

Aardvark Therapeutics (AARD) has 3 years of Accumulated Expenses data on file, last reported at $6.8 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 123.6% year-over-year to $6.8 million; the trailing twelve-month figure through Mar 2026 stood at $6.8 million (up 123.6% YoY), and the FY2025 full-year result was $8.0 million, up 3471.11% from the prior year.
• Accumulated Expenses fell to $6.8 million in Q1 2026, from $8.0 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $8.0 million in Q4 2025 to a low of $225000.0 in Q4 2024.
• A 3-year average of $4.2 million and a median of $3.9 million in 2025 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses soared 3471.11% in 2025 and surged 123.6% in 2026, its largest moves.
• Tracing AARD's Accumulated Expenses over 3 years: stood at $225000.0 in 2024, then soared by 3471.11% to $8.0 million in 2025, then decreased by 15.68% to $6.8 million in 2026.
• Business Quant data shows AARD's Accumulated Expenses at $6.8 million in Q1 2026, $8.0 million in Q4 2025, and $2.2 million in Q3 2025.